Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 3, 2009, Pages 199-210

  Argyriou, Andreas A ^a   Antonacopoulou, Anna ^a   Iconomou, Gregoris ^a   Kalofonos, Haralabos P ^a  

^a University Hospital Rio   (Greece)

Author keywords

Chemotherapy; Gliomas; Neuro oncology; Targeted therapy

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTICONVULSIVE AGENT; BEVACIZUMAB; CARMUSTINE; CCI 79; CEDIRANIB; CETUXIMAB; CILENGITIDE; CISPLATIN; DOXORUBICIN; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GLUCOCORTICOID; IMATINIB; IRINOTECAN; LENALIDOMIDE; LOMUSTINE; LONAFARNIB; NITROSOUREA; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROCARBAZINE; ROMIDEPSIN; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VINCA ALKALOID; VORINOSTAT;

ADJUVANT THERAPY; ANTISENSE THERAPY; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG ERUPTION; DRUG UPTAKE; EDEMA; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; PARENCHYMA; PATHOGENESIS; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR LOCALIZATION;

COMBINED MODALITY THERAPY; GENE THERAPY; GLIOMA; HUMANS;

EID: 63749107805     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.05.005     Document Type: Review

References (100)

1. CBTRUS, statistical report: primary brain tumors in the United States, 1998-2002. Chicago: Central Brain Tumor Registry of the United States (CBTRUS); 2006.
2. Stupp R., Reni M., Gatta G., Mazza E., and Vecht C. Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63 1 (2007) 72-80
3. Lacroix M., Abi-Said D., Fourney D.R., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95 2 (2001) 190-198
4. Omuro A.M., Faivre S., and Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6 7 (2007) 1909-1919
5. Stupp R., Mason W.P., van den Bent M.J., et al., European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 10 (2005) 987-996
6. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5 2 (2003) 79-88
7. Shapiro W.R., Green S.B., Burger P.C., et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76 5 (1992) 772-781
8. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 9311 (2002) 1011-1018
9. Spiegel B.M., Esrailian E., Laine L., and Chamberlain M.C. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 21 9 (2007) 775-787
10. Herrlinger U., Rieger J., Koch D., et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24 27 (2006) 4412-4417
11. Grossman S.A., Wharam M., Sheidler V., et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15 7 (1997) 2596-2603
12. Reardon D.A., Quinn J.A., Rich J.N., et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104 7 (2005) 1478-1486
13. Castellino R.C., Elion G.B., Keir S.T., et al. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother Pharmacol 45 4 (2000) 345-349
14. Hau P., Fabel K., Baumgart U., et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100 6 (2004) 1199-1207
15. Baumann F., Bjeljac M., Kollias S.S., et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 67 1-2 (2004) 191-200
16. Fine H.A., Wen P.Y., Maher E.A., et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21 12 (2003) 2299-2304
17. Lidar Z., Mardor Y., Jonas T., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100 3 (2004) 472-479
18. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35 2 (2001) 161-204
19. See S.J., and Gilbert M.R. Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol 31 5 (2004) 618-634
20. Payne M.J., Pratap S.E., and Middleton M.R. Temozolamide in the treatment of solid tumors: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 53 3 (2005) 241-252
21. van Breemen M.S., Wilms E.B., and Vecht C.J. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6 5 (2007) 421-430
22. Chakravarti A., and Palanichamy K. Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res 139 (2008) 173-189
23. 6-alkylating agents in human glioblastomas. J Clin Oncol 24 2 (2006) 274-287
24. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 19 (2000) 1350-1354
25. 6-alkylguanine DNA alkyltransferase inhibitors. Expert Opin Invest Drugs 16 10 (2007) 1573-1584
26. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59 4 (1999) 793-797
27. 6-Methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis (2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9 4 (2003) 1461-1468
28. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 10 (2005) 997-1003
29. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16 10 (1998) 3310-3315
30. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16 12 (1998) 3851-3857
31. Homma T., Fukushima T., Vaccarella S., et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65 9 (2006) 846-854
32. Houillier C., Lejeune J., Benouaich-Amiel A., et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106 10 (2006) 2218-2223
33. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 25 1 (2005) 1-7
34. Ohgaki H., and Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170 5 (2007) 1445-1453
35. Knobbe C.B., Merlo A., and Reifenberger G. Pten signaling in gliomas. Neuro Oncol 4 3 (2002) 196-211
36. Kato H., Kato S., Kumabe T., et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6 10 (2000) 3937-3943
37. Rasheed B.K., Stenzel T.T., McLendon R.E., et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57 19 (1997) 4187-4190
38. Schmidt E.E., Ichimura K., Messerle K.R., Goike H.M., and Collins V.P. Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. Br J Cancer 75 1 (1997) 2-8
39. Merlo A. Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev 26 3 (2003) 145-158
40. Walker D.G., Duan W., Popovic E.A., Kaye A.H., Tomlinson F.H., and Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55 1 (1995) 20-23
41. Spruck III C.H., Gonzalez-Zulueta M., Shibata A., et al. p16 gene in uncultured tumours. Nature 370 6486 (1994) 183-184
42. Wolter M., Reifenberger J., Blaschke B., et al. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 60 12 (2001) 1170-1180
43. Rao L.S., Miller D.C., and Newcomb E.W. Correlative immunohistochemistry and molecular genetic study of the inactivation of the p16INK4A genes in astrocytomas. Diagn Mol Pathol 6 2 (1997) 115-122
44. Stegh A.H., Kim H., Bachoo R.M., et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21 1 (2007) 98-111
45. Kang D.C., Su Z.Z., Sarkar D., Emdad L., Volsky D.J., and Fisher P.B. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 353 1 (2005) 8-15
46. Emdad L., Sarkar D., Su Z.Z., et al. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther 114 2 (2007) 155-170
47. Rich J.N., and Bigner D.D. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3 5 (2004) 430-446
48. Reardon D.A., and Wen P.Y. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11 2 (2006) 152-164
49. Nakamura J.L. The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications. Expert Opin Ther Targets 11 4 (2007) 463-472
50. Pelloski C.E., Ballman K.V., Furth A.F., et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25 16 (2007) 2288-2294
51. Sathornsumetee S., and Rich J.N. New approaches to primary brain tumor treatment. Anticancer Drugs 17 9 (2006) 1003-1016
52. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 1 (2004) 133-142
53. Franceschi E., Cavallo G., Lonardi S., et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96 7 (2007) 1047-1051
54. Krishnan S., Brown P.D., Ballman K.V., et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 65 4 (2006) 1192-1199
55. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 12 (2005) 880-887
56. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 19 (2005) 2012-2024
57. Vogelbaum M.A., Peereboom D., Stevens G., et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim analysis. Proc Am Soc Clin Oncol 23 (2004) 107 (abstract 1558)
58. Eller J.L., Longo S.L., Kyle M.M., Bassano D., Hicklin D.J., and Canute G.W. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 56 1 (2005) 155-162
59. Jansen M., de Witt Hamer P.C., Witmer A.N., Troost D., and van Noorden C.J. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rev 45 3 (2004) 143-163
60. Takano S., Tsuboi K., Matsumura A., and Nose T. Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts. Neuro Oncol 5 1 (2003) 1-7
61. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 1 (2007) 83-95
62. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 4 (2007) 1253-1259
63. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 30 (2007) 4722-4729
64. Goldbrunner R.H., Bendszus M., Wood J., Kiderlen M., Sasaki M., and Tonn J.C. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55 2 (2004) 426-432
65. Conrad C., Friedman H., Reardon D., et al. A phase I/II trial of single-agent PTK787/ZK222584, a novel oral angiogenesis inhibitor, in patients with recurrent GBM. Proc ASCO (2004) Abstr 1512
66. Wen P.Y., Yung W.K., Lamborn K.R., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12 16 (2006) 4899-4907
67. Marosi C., Vedadinejad M., Haberler C., et al. Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R. Proc Am Soc Clin Oncol 24 (2006) 1526
68. Reardon D.A., Egorin M.J., Quinn J.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23 36 (2005) 9359-9368
69. Desjardins A., Quinn J.A., Vredenburgh J.J., et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83 1 (2007) 53-60
70. Diaz-Flores E., and Shannon K. Targeting oncogenic Ras. Genes Dev 21 16 (2007) 1989-1992
71. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93 14 (2001) 1062-1074
72. Cloughesy T.F., Wen P.Y., Robins H.I., et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24 22 (2006) 3651-3656
73. Gilbert M.R., Gaupp P., Lin V., et al. A phase I study of temozolamide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarasar, SCH66336) in recurrent glioblastoma. Proc Am Soc Clin Oncol 24 (2006) 1556
74. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 16 (2004) 1926-1945
75. Goudar R.K., Shi Q., Hjelmeland M.D., et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4 1 (2005) 101-112
76. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 23 (2005) 5294-5304
77. Goekjian P.G., and Jirousek M.R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Invest Drugs 10 12 (2001) 2117-2140
78. Brandsma D., and van den Bent M.J. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 19 6 (2007) 598-605
79. Halatsch M.E., Schmidt U., Behnke-Mursch J., Unterberg A., and Wirtz C.R. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32 2 (2006) 74-89
80. 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58 3 (2004) 972-975
81. Sampson J.H., Akabani G., Archer G.E., et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65 (1) Oct (2003) 27-35
82. Cohen K.A., Liu T., Bissonette R., Puri R.K., and Frankel A.E. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr Pharm Biotechnol 4 1 (2003) 39-49
83. Vigushin D.M., and Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13 1 (2002) 1-13
84. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., and Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62 1 (2005) 223-229
85. D'Abaco G.M., and Kaye A.H. Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14 11 (2007) 1041-1048
86. MacDonald T.J., Taga T., Shimada H., et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha (v) integrin antagonist. Neurosurgery 48 1 (2001) 151-157
87. Nabors L.B., Rosenfeld S.S., Mikkelsen T., et al. NABTT 9911: a phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. Neuro Oncol 6 (2004) 379
88. Sathornsumetee S., Reardon D.A., Desjardins A., Quinn J.A., Vredenburgh J.J., and Rich J.N. Molecularly targeted therapy for malignant glioma. Cancer 110 1 (2007) 13-24
89. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 5848 (2007) 287-290
90. Rich J.N., Sathornsumetee S., Keir S.T., et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11 22 (2005) 8145-8157
91. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 14 (2003) 4009-4016
92. Rini B.I. Sunitinib. Expert Opin Pharmacother 8 14 (2007) 2359-2369
93. Wang M.Y., Lu K.V., Zhu S., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66 16 (2006) 7864-7869
94. Doherty L., Gigas D.C., Kesari S., et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 1 (2006) 156-158
95. Immonen A., Vapalahti M., Tyynelä K., et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10 5 (2004) 967-972
96. Vecil G.G., and Lang F.F. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 65 3 (2003) 237-246
97. Zhu C.J., Li Y.B., and Wong M.C. Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells. J Neurosci Res 74 (2003) 60-66
98. Sehgal A., Ricks S., Warrick J., Boynton A.L., and Murphy G.P. Antisense human neuroglia related cell adhesion molecule hNr-CAM, reduces the tumorigenic properties of human glioblastoma cells. Anticancer Res 19 (1999) 4947-4953
99. Mukai S., Kondo Y., Koga S., Komata T., Barna B.P., and Kondo S. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 60 (2000) 4461-4467
100. Adachi Y., Chandrasekar N., Kin Y., et al. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 21 (2002) 87-95